HOBOKEN,
N.J., Jan. 15, 2025 /PRNewswire/ -- Quantum
Computing Inc. ("QCi" or the "Company") (Nasdaq: QUBT), an
innovative, integrated photonics and quantum optics technology
company, today announced a collaboration with Sanders
Tri-Institutional Therapeutics Discovery Institute, Inc. (Sanders
TDI) to drive advancement of research in computational biomedicine.
Through this collaboration, QCi will provide Sanders TDI with
access to its quantum computation technology and hardware,
specifically with its Dirac-3 Entropy Quantum Computing Machine, to
support the Institute's experimental work.
Sanders TDI is a non-profit drug discovery institute based in
New York City, composed of
Kettering Cancer Center, The Rockefeller
University, and Memorial Sloan Weill Cornell Medicine. The
Institute's mission is to advance their groundbreaking biological
discoveries to preclinical studies, focusing on the relevance
of these findings for blocking disease initiation and progression.
In addition, Sanders TDI provides industrial-scale technical
support for academic research and projects.
As part of the collaboration, QCi will offer Sanders TDI
cloud-based access to its Dirac-3 systems, which operate at room
temperature and low power and are designed to solve complex
optimization problems.
"We are truly excited to be a part of this strategic
collaboration with Sanders TDI and to have our Dirac-3 systems
support their efforts in rapidly assessing the efficacy of targeted
therapeutics in treating human diseases," stated Dr. William McGann, Chief Executive Officer (CEO) of
QCi. "This partnership exemplifies how QCi's quantum machines can
provide powerful insights and useful analyses today. It aligns
perfectly with our mission to make quantum machines accessible and
affordable and is one of the many real-world applications where the
power of quantum computing is being demonstrated and put into
practice by QCi."
The collaboration will focus on advancing Sanders TDI's
computational chemistry research by leveraging quantum
technologies, including quantum analog computers, for proof of
concept calculations in biomolecular modeling. Recognizing the
diverse set of potential use cases in this field, QCi will work
closely with Sanders TDI to explore a variety of quantum-enabled
applications, with the goal of identifying the most promising use
cases for its Dirac systems.
To learn more about how QCi is driving the future of accessible
and affordable photonic technology or to explore collaboration
opportunities, please visit the QCi webpage.
About Quantum Computing Inc.
Quantum Computing Inc. (Nasdaq: QUBT) is an innovative,
integrated photonics and quantum optics technology company that
provides accessible and affordable quantum machines to the world
today. QCi's products are designed to operate at room temperature
and low power at an affordable cost. The Company's portfolio of
core technologies and products offer unique capabilities in the
areas of high-performance computing, artificial intelligence, and
cybersecurity, as well as remote sensing applications.
For investor relations inquiries, contact John Nesbett
at qci@imsinvestorrelations.com, and for public relations
inquiries, contact Jessica Tocco
at jessica.tocco@a10associates.com.
Forward-Looking Statements
This press release contains forward-looking statements as
defined within Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These forward-looking statements and forecasts, generally
identified by terms such as "may," "will," "expect," "believe,"
"anticipate," "estimate," "intends," "goal," "objective," "seek,"
"attempt," "aim to," or variations of these or similar words,
involve risks and uncertainties because they relate to events and
depend on circumstances that will occur in the future. Those
statements include statements regarding the intent, belief, or
current expectations of QCi and members of its management as well
as the assumptions on which such statements are
based. Prospective investors are cautioned that any such
forward-looking statements are not guarantees of future performance
and involve risks and uncertainties, including the development of
biomedical quantum applications, and that actual results may differ
materially from those contemplated by such forward-looking
statements. Except as required by federal securities law, QCi
undertakes no obligation to update or revise forward-looking
statements to reflect changed conditions.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/quantum-computing-inc-announces-collaboration-with-sanders-tri-institutional-therapeutics-discovery-institute-to-support-research-using-dirac-3-systems-302351488.html
SOURCE Quantum Computing Inc.